Helix BioMedix Receives Key US Patent for its Bioactive Peptides
Helix BioMedix announced the issuance of U.S. Patent No. 6,875,744 entitled "Short Bioactive peptides." The patent covers a vast family of bioactive peptides designed for low cost synthesis and improved bioactivity. Specifically, this patent covers the composition of matter and use for peptides of five to 22 amino acids in length that consist, in large part, of four specific amino acids. This patent significantly expands the Company's technology platform of proprietary peptides for therapeutic and consumer product applications.
Peptides included in this patent form the basis of preclinical programs at Helix targeted at preventing wound infections and sexually transmitted diseases. In addition, this patent extends the Company's worldwide competitive edge in designing inexpensive peptides, a critical factor for the consumer goods market. In total, the Company now has nine issued patents in the U.S., nine issued foreign patents and four patents pending. Helix currently has research applications in such consumer markets as acne, skin care, wrinkle reduction, deodorants, and oral care. Based upon activities of peptides observed in nature, Helix has made advancements in all of these applications by exploiting the anti-infective and stimulatory properties of these short bioactive peptides.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.